BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Open|| Long (1Y)
Nomura Recommends 'Buy' On Sun Pharma
According to Nomura, the sensitivity of Halol earnings is currently low for Sun Pharma compared to December 2015, when the unit had received a warning letter, with limited expectations of an upside from generic launches. Scaling up of specialty sales is the key earnings driver for the company, the brokerage adds.